Breast Cancer Research and Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 9, 2024 Category: Cancer & Oncology Source Type: research

Body composition measures as a determinant of Alpelisib related toxicity
ConclusionBody composition measures, specifically SMD and VAT may provide an opportunity to identify patients at higher risk for severe alpelisib related hyperglycemia, and cutaneous toxicity. These findings suggest the potential use of body composition assessment to caution toxicity risk, allowing for personalized therapeutic observation and intervention. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 7, 2024 Category: Cancer & Oncology Source Type: research

Breast cancer (BC) and severe COVID-19 (C-19) outcomes: a matched analysis
ConclusionPatients with BC have a similar risk of adverse C-19 outcomes compared to patients without cancer. Among patients with BC, recent chemotherapy was associated with a higher risk of hospitalization. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 6, 2024 Category: Cancer & Oncology Source Type: research

Circulating tumour DNA dynamics during alternating chemotherapy and hormonal therapy in metastatic breast cancer: the ALERT study
ConclusionChanges in ctDNA can occur rapidly and reflect changes in patients ’ clinical tumour responses (NCT02681523). (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 6, 2024 Category: Cancer & Oncology Source Type: research

Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value
ConclusionCathepsin D expression significantly predicts poor prognosis in breast cancer and is associated with variables of poor prognosis and shorter outcome. The strong association of Cathepsin D with aggressive tumour characteristics and poor outcomes warrants further research of its potential as a therapeutic target The results also suggest a possible interaction between Cathepsin D and tamoxifen therapy in ER-positive breast cancer which needs further investigation to elucidate the underlying mechanisms. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 5, 2024 Category: Cancer & Oncology Source Type: research

BRCA1/2 mutation carriers vs the general breast cancer population (N  = 799,986): 21-gene assay-based molecular characterization
ConclusionBC patients with PVs inBRCA1/2 have higher RS results that stem from distinct gene expression profiles in the majority of genes in the 21-gene assay. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 3, 2024 Category: Cancer & Oncology Source Type: research

Global prevalence and factors associated with preoperative depression in women undergoing breast surgery: a meta-analysis and meta-regression
ConclusionThe high prevalence of preoperative depression among women with breast cancer indicated the need for health care professionals to provide more psychological support to them. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 16, 2024 Category: Cancer & Oncology Source Type: research

Retrospective genetic testing (Traceback) in women with early-onset breast cancer after revised national guidelines: a clinical implementation study
ConclusionThe insights from the participants ’ perspectives and sentiments throughout the process support the notion that the Traceback procedure is a safe and an appreciated complement to routine genetic counseling. The genetic yield of almost 10% also suggests that the associated extra workload for genetic counselors could be viewed as acc eptable in clinical implementation scenarios. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 16, 2024 Category: Cancer & Oncology Source Type: research

False negative breast cancers on imaging and associated risk factors: a single institution six-year analysis
ConclusionOur findings suggest that supplemental screening may be useful in breast cancer survivors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 14, 2024 Category: Cancer & Oncology Source Type: research

Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases
ConclusionBaseline serum MMA levels in patients with breast cancer are not correlated with secondary distant metastasis. Evidence in the mouse model suggests that the presence of a tumor perturbates MMA levels. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 13, 2024 Category: Cancer & Oncology Source Type: research

Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants
ConclusionLCIS has both an immediate risk (19.3%) and a delayed risk (18.6%) for cancer with 90.9% occurring in the ipsilateral breast (63.6% at and 27.3% away from the site of LCIS) and 9.1% occurring in the contralateral breast. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 12, 2024 Category: Cancer & Oncology Source Type: research

Infertility and risk of postmenopausal breast cancer in the women ’s health initiative
ConclusionThese findings suggest that infertility may be modestly associated with future risk of postmenopausal breast cancer due to age at first pregnancy and highlight the importance of incorporating reproductive history across the life course into breast cancer analyses. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 9, 2024 Category: Cancer & Oncology Source Type: research

Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab
ConclusionThese findings suggest a potential role of Trop-2 expression as a biomarker of resistance to neoadjuvant chemotherapy plus dual HER2 blockade and may become a strategic target for future combinations in HER2-positive EBC patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 8, 2024 Category: Cancer & Oncology Source Type: research

Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade
ConclusionOver the last decade, the median OS of patients with brain metastases at initial breast cancer diagnosis remained poor; however, a substantial minority survive 5 or more years, with rates higher in patients with HER2-positive tumors. In addition to tumor subtype, OS varied according to age, extracranial metastases, and sociodemographic factors. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 7, 2024 Category: Cancer & Oncology Source Type: research

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2  + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
ConclusionOur results showed high pCR rates with Trastuzumab and Pertuzumab associated to chemotherapy. They were similar in TOP2A  + and TOP2A- groups and the current role of neoadjuvant anthracycline-based chemotherapy remains questioned.Trial registration numberNCT02339532 (registered on 14/12/14). (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - March 7, 2024 Category: Cancer & Oncology Source Type: research